Combination therapy comprising ribavirin and interferon alpha in antiviral treatment haive patients having g chronic hepatitis C infection

Details for Australian Patent Application No. 2005220271 (hide)

International Classifications

Event Publications

27 October 2005 Complete Application Filed

3 November 2005 Application Open to Public Inspection

Published as AU-B-2005220271

12 February 2009 Application Accepted

Published as AU-B-2005220271

28 May 2009 Opposition Lodged

Sandoz AG has lodged an opposition against Schering Corporation.

28 October 2010 Opposition Withdrawn

The opposition by Sandoz AG against Schering Corporation has been withdrawn.

18 November 2010 Corrigenda

Applications Accepted - Name Index Under the name Schering Corporation, Application No. 2005220271, under INID (54) correct the title to read Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis C infection

25 November 2010 Standard Patent Sealed

11 October 2012 Application for Amendment

The nature of the amendment is: Amend the Patentee to read Merck Sharp & Dohme Corp. . Address for service in Australia - Griffith Hack Level 29, Northpoint 100 Miller Street North Sydney NSW 2060

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.